Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 16/20 | 0.67 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5835327 | 1.00 | UTS2R (0.67) | UTS2RERBB2EPHA2KDREPHB4 | |
| SCHEMBL5835494 | 0.88 | UTS2R (0.70) | UTS2RERBB2EPHA2KDREPHB4 | |
| SCHEMBL5835495 | 0.88 | UTS2R (0.70) | UTS2RERBB2EPHA2KDREPHB4 | |
| SCHEMBL5835278 | 0.88 | UTS2R (0.62) | UTS2RLMNAHTR2CHTR2B | |
| SCHEMBL5835275 | 0.88 | UTS2R (0.62) | UTS2RLMNAHTR2CHTR2B | |
| SCHEMBL5835488 | 0.88 | UTS2R (0.64) | UTS2RLMNAHTR2CHTR2B | |
| SCHEMBL5835485 | 0.88 | UTS2R (0.64) | UTS2RLMNAHTR2CHTR2B | |
| SCHEMBL5835567 | 0.88 | UTS2R (0.66) | UTS2RLMNAHTR2CHTR2B | |
| SCHEMBL5835566 | 0.88 | UTS2R (0.66) | UTS2RLMNAHTR2CHTR2B | |
| SCHEMBL5835130 | 0.86 | UTS2R (0.68) | UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026349-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-11 | — | — | US | claimed |
| US-20040152906-A1 | Sulfonamides | SHELL OIL COMPANY | 2004-08-05 | — | — | US | claimed |
| US-7026349-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1385507-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20040152906-A1 | Sulfonamides | SHELL OIL COMPANY | 2004-08-05 | — | — | US | disclosed |
| EP-1385507-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002089792-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152906-A1 | Sulfonamides | UTS2R, PRSS2, STS | UTS2R 1/4885ERBB2 1154/4885EPHA2 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.